
New Studies Dismiss Signs of Life on Distant Planet
In April, a team of astronomers announced that they might — just might — have found signs of life on a planet over 120 light-years from Earth. The mere possibility of extraterrestrial life was enough to attract attention worldwide. It also attracted intense scrutiny from other astronomers.
Over the past month, researchers have independently analyzed the data, which suggested that the planet, called K2-18b, has a molecule in its atmosphere that could have been created by living organisms. Three different analyses have all reached the same conclusion: They see no compelling evidence for life on K2-18b.
'The claim just absolutely vanishes,' said Luis Welbanks, an astronomer at Arizona State University and an author of one of the studies.
The debate has less to do with the existence of alien life than with the challenge of observing distant planets. We can see a nearby planet like Jupiter because it reflects enough sunlight to become visible to the naked eye. But a planet like K2-18b is so far away that it becomes invisible not just to the naked eye but to conventional telescopes.
Astronomers have devised a series of increasingly sophisticated tricks to glean information about distant planets. They can measure the wobble of stars and the gravity of planets orbiting them. In 2010, researchers caught a glimpse of GJ 1214b, a planet 48 light-years away, as it passed in front of the star it orbits. When the star's light shined through the planet's atmosphere, certain wavelengths were absorbed indicating that GJ 1214b might have an atmosphere rich in water vapor.
In 2022, astronomers began using a powerful new tool to peer at distant planets this way. They pointed the James Webb Space Telescope at faraway solar systems and began detecting exquisitely faint patterns in starlight, clues to the complexity of exoplanet atmospheres.
The following year, Nikku Madhusudhan, an astronomer at the University of Cambridge, and his colleagues zeroed in on K2-18b as it passed in front of its own star, using instruments on the Webb telescope that are exquisitely sensitive to near-infrared light. As K2-18b passed in front of the star, the starlight underwent a subtle shift — caused by a planetary atmosphere containing hydrogen, carbon dioxide and methane, the researchers concluded.
They also found suggestive hints of a fourth gas, dimethyl sulfide — which could be a very big deal. On Earth, the only source for dimethyl sulfide in the atmosphere is life. Photosynthetic microbes in the ocean produce the molecule as a defense against ultraviolet light from the sun. The molecule escapes their cells and ends up in the air.
But the signal was so faint that it was hard to be certain that it was real. So Dr. Madhusudhan's team arranged to look again at K2-18b, in 2024. This time, they used a different instrument on the space telescope, which looks at longer wavelengths of mid-infrared light.
In the team's second search, they again found a signature of dimethyl sulfide, this one seemingly even stronger than the first. In April, Dr. Madhusudhan and his colleagues described their results in a paper published in Astrophysical Journal Letters. Speaking at a news conference the day before, Dr. Madhusudhan said there was only 'a three-in-a-thousand chance of this being a fluke.'
Rafael Luque, an astronomer at the University of Chicago, characterized Dr. Madhusudhan as a world expert on exoplanets. 'Madhu has been a pioneer in the field,' he said. 'I have the utmost respect for that team.'
Nevertheless, Dr. Luque and his colleagues decided to take a look at the data for themselves.
For their own analysis, the scientists combined all the observations of K2-18b in both the near-infrared and mid-infrared wavelengths. On Monday, they reported that this combined data contained strong signals of hydrogen, carbon dioxide and methane, but no clear evidence of dimethyl sulfide.
The critics argue that the new mid-infrared observations were much weaker than those in near-infrared. On its own, they say, the mid-infrared light could fool researchers with faint noise masquerading as a real signal of dimethyl sulfide.
'I can just say straight up there is no statistically significant signal in the data that were published a month ago,' said Jacob Bean. Dr. Bean, an astronomer at the University of Chicago who discovered GJ 1214b's atmosphere, worked with Dr. Luque on Monday's study.
Dr. Welbanks, a former student of Dr. Madhusudhan's, and his colleagues analyzed the K2-18b data in a different way. If the mid-infrared signal was genuine, did it have to come from dimethyl sulfide?
The team considered 90 different molecules that could plausibly be produced on a planet like K2-18b. Those molecules didn't have to be produced by life, however; chemical reactions driven by sunlight could be enough.
The researchers concluded that the mid-infrared signal might have been produced by 59 of the 90 molecules. The strongest candidate in their analysis was not dimethyl sulfide but propyne, a gas that welders use as fuel.
Dr. Welbanks and his colleagues aren't claiming that propyne is actually present on K2-18b. They simply argue that the faint light from the planet's atmosphere can create ambiguous patterns that might be the result of one of many gases. Such scanty data certainly isn't sufficient to consider any planet to be a possible home for life.
Last week, Dr. Madhusudhan and his colleagues responded to Dr. Welbanks's team with a study of their own. They examined 650 possible molecules that might be in K2-18b's atmosphere; dimethyl sulfide ended up among the molecules at the top of the list. 'We're exactly where we left off a month ago; it's a good candidate,' Dr. Madhusudhan said.
Dr. Welbanks said that the new study by Dr. Madhusudhan simply provided more evidence that dimethyl sulfide does not stand out compared to other possible molecules on K2-18b. 'In effect, this is a self-rebuttal,' he said.
It's possible that the debate over K2-18b could be resolved within months. Last year Renyu Hu, an astronomer at the Jet Propulsion Laboratory, and his colleagues made more near-infrared observations of the planet. They are now preparing their results. 'It will include substantially more data than previously published,' Dr. Hu said.
Dr. Bean said that the new observations could dispel much of the confusion about K2-18b. 'The science is definitely working,' he said. 'It's going to play out pretty quickly, and I think we'll have some clarity.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Verge
18 minutes ago
- The Verge
Who needs a real expert when you have a crypto bro?
The National Science Foundation — which developed tech such as the literal internet — now has a 23-year-old to veto funding to projects he doesn't understand. That's DOGE's Zachary Terrell, who can barely pretend to pay attention in meetings. Anyway, this is who's deciding which grants go forward — some guy with no experience in anything except getting a company acquired by Coinbase. Scientific experts? Those are a luxury for functioning countries.


Entrepreneur
28 minutes ago
- Entrepreneur
Paradigm Shift in MDS Treatment: Faron Pharmaceuticals Unveils Landmark Phase II Trial Data at ASCO 2025
The ability to not only extend life but also improve quality of life by reducing transfusion needs and infection rates is what sets this treatment apart You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media. In a field long hindered by stagnation, Faron Pharmaceuticals may have just turned a critical corner in the fight against high-risk myelodysplastic syndromes (HR-MDS). The Finnish clinical-stage biopharmaceutical company unveiled highly promising results from its Phase II BEXMAB trial at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The updated data, presented during a Rapid Oral Abstract Session by Dr. Naval Daver of MD Anderson Cancer Center, revealed that Faron's investigational immunotherapy, bexmarilimab (bex), when combined with the standard-of-care drug azacitidine, achieved a median overall survival (mOS) of 13.4 months in patients with relapsed/refractory (r/r) MDS, which is more than double the typical 5-6 months expected under current treatments. "These are patients who historically have had virtually no effective options after standard HMA therapies fail," said Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals. "To see such meaningful survival and response rates gives us real hope that we're on the path to a true therapeutic breakthrough." The study reported an objective response rate (ORR) of 63% in r/r MDS patients (n=32) and an even higher ORR of 72% in treatment-naïve, frontline HR-MDS patients (n=18). Moreover, 56% experienced a complete (100%) reduction. Under the recently updated 2023 International Working Group (IWG) criteria, the composite complete response (cCR) rate was 56%, more than double the typical 25% response seen with azacitidine alone. Bex is a first-in-class monoclonal antibody targeting the Clever-1 receptor, a key mediator in immune suppression within the tumor microenvironment. By blocking Clever-1, the drug reprograms macrophages in the bone marrow, enabling them to mount a more effective anti-tumor immune response. "The ability to not only extend life but also improve quality of life by reducing transfusion needs and infection rates is what sets this treatment apart," confirmed Dr. Juho. "This is especially critical for a patient population that is often elderly and frail." Indeed, the therapy has demonstrated a favorable safety profile. No new safety concerns were reported, and the treatment was well-tolerated even among patients with severe anemia and recurrent infections. The impressive data from the BEXMAB study supports Faron's plan to move forward with a registrational Phase III trial comparing bex + azacitidine versus placebo + azacitidine in frontline HR-MDS. Discussions with the FDA are scheduled for an upcoming end-of-Phase II meeting. "Given the strong correlation between cCR and survival under the new IWG 2023 guidelines, we believe this could form the basis for accelerated approval," Dr. Juho stated. As the oncology community digests the implications of this data, one thing is clear: Faron Pharmaceuticals has taken a bold step forward in its mission to reshape cancer treatment through immune reprogramming.


Fox News
32 minutes ago
- Fox News
Daily coffee drinking linked to major health benefit in women as they age, study finds
A popular morning beverage could do more than provide a perk — it could also help women stay healthy as they age. That's according to new research from Harvard University, which followed a group of nearly 50,000 women from the Nurses' Health Study for a 30-year period. The researchers found that drinking coffee every morning could help women stay mentally sharp and physically strong later in life, according to a press release from the American Society of Nutrition. The benefits were seen in middle-aged women who drank caffeinated coffee. Decaf coffee and tea did not have the same effect. "'Healthy aging' here meant surviving to older age without major chronic diseases and with good physical, mental and cognitive function," Dr. Sara Mahdavi, Ph.D., a post-doctoral fellow at Harvard T.H. Chan School of Public Health, Harvard University, told Fox News Digital. "Importantly, this relationship persisted even after accounting for key lifestyle factors like diet quality, physical activity and smoking — each of which are also strongly associated with healthy aging in their own right." The women who qualified as "healthy agers" were found to consume an average of 315 mg of caffeine daily, primarily via coffee-drinking. Each additional cup of coffee was linked to a 2% to 5% greater chance of healthier aging, the study found. Although soda also contains caffeine, people who drank it every day were shown to have a 20% to 26% reduced chance of healthy aging. "The health benefits appeared specific to coffee, rather than caffeine more broadly," Mahdavi noted. "We didn't see the same associations with decaf coffee, tea or caffeinated soda — suggesting that coffee's unique combination of bioactive compounds may play a key role." The findings were set to be presented on Monday at NUTRITION 2025, the annual meeting of the American Society for Nutrition held in Orlando. "While past studies have linked coffee to individual health outcomes, our study is the first to assess coffee's impact across multiple domains of aging over three decades," said Mahdavi. "The findings suggest that caffeinated coffee … may uniquely support aging trajectories that preserve both mental and physical function." "The health benefits appeared specific to coffee, rather than caffeine more broadly." The researcher acknowledged that the study has some limitations. "As with all observational studies, we cannot establish causality," she told Fox News Digital. "While we adjusted for many factors, unmeasured confounding is always possible." Mahdavi also pointed out that the study group mostly included white, educated female health professionals. "Further work is needed to confirm generalizability to broader populations." Coffee's benefits are "relatively modest" compared to the benefits of overall healthy lifestyle habits, according to the researcher. "These results, while preliminary, suggest that small, consistent habits can shape long‑term health," said Mahdavi. "Moderate coffee intake may offer some protective benefits when combined with other healthy behaviors, such as regular exercise, a healthy diet and avoiding smoking." "We don't recommend starting coffee if you don't already drink it or if you're sensitive to caffeine," she went on. "But for people who already consume moderate amounts — typically two to four cups per day — this study adds to the evidence that coffee can be part of a healthy lifestyle." Mahdavi emphasized, however, that nutrition, regular exercise and not smoking are the "most powerful and proven contributors" to healthy aging. The team is now planning to explore how coffee's bioactive compounds — particularly polyphenols and antioxidants — might influence molecular aging pathways, including inflammation, metabolism and vascular health, Mahdavi said. For more Health articles, visit "Genetic and hormonal differences may also shape how individuals respond, which could pave the way for more personalized guidance in the future."